Program
golcadomide
Also written as “BMS-986369”, “Golcadomide” and “CC-99282”.
Its studies are mostly in Lymphoma, Follicular · Lymphoma, Non-Hodgkin · Lymphoma, T-Cell · Kidney Failure, Chronic · Lymphoma, B-Cell, led by Bristol-Myers Squibb.
Furthest: phase 3, since Mar 27, 202411 company-led studies, 7 open or runningNext primary completion: Dec 14, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 117 open or running | phase 3since Mar 27, 2024 | Apr 16, 2019 | Dec 14, 2026phase 1 · NCT07763418 |
- Named in Bristol-Myers Squibb’s own pipeline as
golcadomide
, phase 3, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 16, 2019First study: phase 2 study in Lymphoma, Non-HodgkinFirst studyNCT03930953 · 438 enrolled · United States, Argentina, Austria and more
- Jun 1, 2020Phase 1 study in Lymphoma, Non-HodgkinNCT04434196 · 16 enrolled · United States, Austria, Canada and more
- May 7, 2021Phase 1 study in Lymphoma, B-CellNCT04884035 · 224 enrolled · United States, Australia, Greece and more
- Apr 25, 2022Phase 1 study in Healthy VolunteerNCT05350800 · 68 enrolled · United States
- Oct 3, 2022Phase 1 study in Healthy ParticipantsNCT05567510 · 8 enrolled · United States
- Aug 28, 2023Phase 2 study in RecurrenceNCT06035497 · 83 enrolled · Japan
- Mar 27, 2024Phase 3 study in LymphomaNCT06356129 · 850 enrolled · United States, Argentina, Australia and more
- May 17, 2024Phase 2 study in Lymphoma, FollicularNCT06425302 · 95 enrolled · United States, Australia, Brazil and more
- Jul 30, 2024Phase 1 study in Liver DiseasesNCT06535399 · 29 enrolled · United States
- Mar 28, 2025Phase 3 study in Lymphoma, FollicularNCT06911502 · 400 planned · United States, Australia, Brazil and more
- Aug 10, 2026Phase 1 study in Kidney Failure, ChronicNCT07763418 · 30 planned · United States
Ahead
- Dec 14, 2026Primary completion: phase 1 study in Kidney Failure, ChronicNCT07763418
- Apr 7, 2027Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT03930953
- Aug 9, 2027Primary completion: phase 3 study in LymphomaNCT06356129
- Apr 24, 2028Primary completion: phase 3 study in Lymphoma, FollicularNCT06911502
TargetBeta
“A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, golcadomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and target…”NCIt, read by Claude
Other programs on CRBN
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lenalidomiderule | Bristol-Myers Squibb | phase 4 | 109 |
| pomalidomiderule | Bristol-Myers Squibb | phase 4 | 51 |
| mezigdomide | Bristol-Myers Squibb | phase 3 | 12 |
| Cereblon E3 Ubiquitin Ligase Modulating Drug BMS-986506 | Bristol-Myers Squibb | phase 1 | 1 |
| HRS-3738 | Jiangsu HengRui Medicine | phase 1 | 1 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07763418Kidney Failure, Chronic · United States | 1 | Recruiting | Dec 14, 2026 | 30 |
| NCT06911502Lymphoma, Follicular · United States, Australia, Brazil and more | 3 | Recruiting | Apr 24, 2028 | 400 |
| NCT06535399Liver Diseases · United States | 1 | Completed | Nov 12, 2025 | 29 |
| NCT06425302Lymphoma, Follicular · United States, Australia, Brazil and more | 2 | Active, not recruiting | Jun 19, 2026 | 95 |
| NCT06356129Lymphoma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 9, 2027 | 850 |
| NCT06035497Recurrence · Japan | 2 | Active, not recruiting | Aug 11, 2026 | 83 |
| NCT05567510Healthy Participants · United States | 1 | Completed | Dec 27, 2022 | 8 |
| NCT05350800Healthy Volunteer · United States | 1 | Completed | May 4, 2023 | 68 |
| NCT04884035Lymphoma, B-Cell · United States, Australia, Greece and more | 1 | Active, not recruiting | Dec 1, 2028 | 224 |
| NCT04434196Lymphoma, Non-Hodgkin · United States, Austria, Canada and more | 1 | Completed | May 21, 2024 | 16 |
| NCT03930953Lymphoma, Non-Hodgkin · United States, Argentina, Austria and more | 2 | Active, not recruiting | Apr 7, 2027 | 438 |
How it is read
Names in the registry
- “BMS-986369”, 4 entries
- “Golcadomide”, 4 entries
- “CC-99282”, 3 entries
Conditions, from the studies’ own filings
- Lymphoma, Follicular, 2 studies
- Lymphoma, Non-Hodgkin, 2 studies
- Lymphoma, T-Cell, 1 study
- Kidney Failure, Chronic, 1 study
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.